Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways

• Hauptverfasser: Hosford SR (Verfasst von), Miller TW (Verfasst von)
• Format: Buch
• Veröffentlicht: Dove Medical Press, 2014-08-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Sarah R Hosford,1 Todd W Miller1,2 1Department of Pharmacology and Toxicology, 2Comprehensive Breast Cancer Program, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA Abstract: Breast cancers expressing estrogen receptor α, progesterone receptor, or the...